Optimized human-derived antibodies against bacterial and viral infectious diseases, as well as cancer

Bacteria Intro Tile Virus Intro Tile Cancer Intro Tile

Latest News and Publications

July 17, 2017 - Bacteria Publication: “A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections” AAC/ASM

July 19, 2017 - Cancer Publication: “High affinity anti-TIM-3 and anti-KIR monoclonal antibodies cloned from healthy human individuals.” PLOS ONE

Body with mAbs

See how we are fighting the global threat of antibiotic resistance with our anti-biofilm antibody, TRL1068 >>

Biofilm Intro Tile

Harnessing the Human Immune System

The immune system is nature’s most powerful weapon against disease. Trellis Bioscience is an NIH and venture-funded biotechnology company that leverages its proprietary CellSpot™ technology to derive rare, naturally optimized antibodies from healthy donor blood against infectious diseases and cancer.

Due to their human origin, our therapeutics are safer and more effective than alternatives.

Our Technology

Using our proprietary CellSpot Platform we discover the most effective antibodies in healthy donor blood for therapeutic use in non-immune patients

Our Therapeutic Candidates

Trellis has derived five human monoclonal antibody (mAbs) therapeutics against bacterial, viral and cancer indications. All candidates are in preclinical development and will reach Phase I clinical trials by 2019.

Biofilm Tile HCMV Tile Pan-influenza Tile RSV Tile Cancer Tile

In vivo and in vitro experimental data show our antibodies possess superior binding affinity, broad-spectrum capabilities, and efficacy compared to alternative therapies

Biofilm is a leading cause of antibiotic resistance. This Scanning Electron Microscropy photograph at 4000X magnification shows our antibody, TRL1068, disrupting biofilm in Pseudomonas aeruginosa, a multi-drug resistant, gram-negative bacteria species.

Antibiotic Resistant

Antibiotic Susceptible

OUR COMPANY


We are business leaders and scientists passionate about developing human antibody therapies to various diseases.

Our team offers diverse academic and operational expertise, covering all stages of drug development:

1) Discovery

2) Preclinical Development

3) Clinical Trials

4) Commercialization

© 2010-2018 TRELLIS BIOSCIENCE. ALL RIGHTS RESERVED.